Agios Pharmaceuticals, Inc. (AGIO)

Trade AGIO now with
4/1/2021 7:17:35 AM Agios Closes Sale Of Commercial, Clinical And Research-stage Oncology Portfolio To Servier
12/1/2020 7:17:25 AM Agios: Phase 3 ACTIVATE Trial Of Mitapivat Met Its Primary Endpoint
11/12/2020 4:58:37 PM Agios Says FDA Orphan Drug Designation Granted To Mitapivat For Treatment Of Sickle Cell Disease
9/8/2020 4:15:45 PM Agios Appoints Jonathan Biller As CFO
5/19/2020 7:18:58 AM Agios Pharma Says The Lancet Oncology Publishes Data From Global Phase 3 ClarIDHy Study Of TIBSOVO
3/23/2020 7:13:03 AM Agios Says FDA Cleared Investigational New Drug Application For AG-946
1/12/2020 8:06:42 PM Agios Expects To Have 4 Marketed Products In At Least 8 Indications, At Least 6 Molecules In Development In 2025
6/13/2016 9:34:48 AM Canaccord Ups Agios Pharmaceuticals, Inc. (AGIO) To Buy From Hold With $90 Up From $50 Price Target
3/4/2016 10:22:52 AM Canaccord Is Lowering Agios Pharmaceuticals, Inc. (AGIO) 2016 Rev. Estimate To 84 M From 119 M
3/4/2016 10:21:31 AM Canaccord Is Cutting Agios Pharmaceuticals, Inc. (AGIO) 2016 Estimate To -3.73 From -2.10